BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17848574)

  • 1. MDM2 chaperones the p53 tumor suppressor.
    Wawrzynow B; Zylicz A; Wallace M; Hupp T; Zylicz M
    J Biol Chem; 2007 Nov; 282(45):32603-12. PubMed ID: 17848574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
    Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
    Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1.
    Stevens C; Pettersson S; Wawrzynow B; Wallace M; Ball K; Zylicz A; Hupp TR
    FEBS J; 2008 Oct; 275(19):4875-86. PubMed ID: 18754770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein.
    Walerych D; Gutkowska M; Klejman MP; Wawrzynow B; Tracz Z; Wiech M; Zylicz M; Zylicz A
    J Biol Chem; 2010 Oct; 285(42):32020-8. PubMed ID: 20688913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
    Sasaki M; Nie L; Maki CG
    J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization.
    Peng Y; Chen L; Li C; Lu W; Chen J
    J Biol Chem; 2001 Nov; 276(44):40583-90. PubMed ID: 11507088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
    Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
    J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 chaperones wild-type p53 tumor suppressor protein.
    Walerych D; Kudla G; Gutkowska M; Wawrzynow B; Muller L; King FW; Helwak A; Boros J; Zylicz A; Zylicz M
    J Biol Chem; 2004 Nov; 279(47):48836-45. PubMed ID: 15358769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.
    Esser C; Scheffner M; Höhfeld J
    J Biol Chem; 2005 Jul; 280(29):27443-8. PubMed ID: 15911628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 mRNA controls p53 activity by managing Mdm2 functions.
    Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
    Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
    Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
    Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 Inhibits Axin-Induced p53 Activation Independently of its E3 Ligase Activity.
    He Y; Lian G; Lin S; Ye Z; Li Q
    PLoS One; 2013; 8(6):e67529. PubMed ID: 23826318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53.
    King FW; Wawrzynow A; Höhfeld J; Zylicz M
    EMBO J; 2001 Nov; 20(22):6297-305. PubMed ID: 11707401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2.
    Joo HM; Kim JY; Jeong JB; Seong KM; Nam SY; Yang KH; Kim CS; Kim HS; Jeong M; An S; Jin YW
    Eur J Cell Biol; 2011 May; 90(5):420-31. PubMed ID: 21333377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.